KLK3 and prostate carcinoma: A phase-II clinical report on capsule delivery for 2 ME revealed safe and adequate therapeutic potential toward decreasing PSA velocity in castration-resistant prostate cancer patients; however, it was lacking to maintain sufficient plasma concentration of 2 ME for a longer time (Sweeney et al., 2005).